Ascendis Pharma A/S(ASND)Earnings, Financials & Key Ratios
ASND•NASDAQ
$225.28
$13.83B mkt cap·Price updated May 6, 2026
AboutAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Show more
- Revenue$692M+90.2%
- EBITDA-$114M+56.4%
- Net Income-$219M+42.1%
- EPS (Diluted)-3.62+44.6%
- Gross Margin85.08%-3.1%
- EBITDA Margin-16.47%+77.1%
- Operating Margin-18.92%+75.3%
- Net Margin-31.67%+69.5%
- ROIC-69.07%+34.5%
- Interest Coverage-1.69+64.0%
ASND Key Insights
Ascendis Pharma A/S (ASND) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 150.9%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ASND Price & Volume
Ascendis Pharma A/S (ASND) stock price & volume — 10-year historical chart
Loading chart...
ASND Growth Metrics
Ascendis Pharma A/S (ASND) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years55.97%
5 Years150.93%
3 Years138.21%
TTM97.4%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM39.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM39.76%
Return on Capital
10 Years-80.27%
5 Years-106.73%
3 Years-134.54%
Last Year-51.87%
ASND Recent Earnings
Ascendis Pharma A/S (ASND) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 6/12 qtrs (55%)
Q1 2026Latest
Feb 11, 2026EPS
$0.64
Est $0.06
-966.7%
Revenue
$345M
Est $292M
+18.0%
Q4 2025
Nov 12, 2025EPS
$1.17
Est $0.41
-185.4%
Revenue
$250M
Est $303M
-17.3%
Q3 2025
Aug 7, 2025EPS
$0.93
Est $1.42
+34.5%
Revenue
$186M
Est $233M
-20.2%
Q2 2025
May 1, 2025EPS
$1.66
Est $1.56
-6.4%
Revenue
$111M
Est $153M
-27.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 11, 2026 | $0.64vs $0.06-966.7% | $345Mvs $292M+18.0% |
| Q4 2025 | Nov 12, 2025 | $1.17vs $0.41-185.4% | $250Mvs $303M-17.3% |
| Q3 2025 | Aug 7, 2025 | $0.93vs $1.42+34.5% | $186Mvs $233M-20.2% |
| Q2 2025 | May 1, 2025 | $1.66vs $1.56-6.4% | $111Mvs $153M-27.9% |
Based on last 12 quarters of dataView full earnings history →
ASND Peer Comparison
Ascendis Pharma A/S (ASND) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IONS | 12.44B | 75.25 | -31.62 | 33.87% | -30.87% | -58.57% | 5.35 | |
 INCY | 19.47B | 97.47 | 15.21 | 21.22% | 26.71% | 29.31% | 6.96% | 0.01 |
 ALKS | 6.12B | 36.25 | 25.35 | -5.25% | 16.37% | 14.45% | 7.85% | 0.04 |
 JAZZ | 13.32B | 212.26 | -36.35 | 4.88% | 0.66% | 0.71% | 9.74% | 1.26 |
 ACAD | 3.78B | 22.35 | 16.43 | 31.85% | 24.94% | 28.47% | 4.16% | 0.07 |
 RARE | 2.46B | 25.01 | -4.29 | 20.13% | -85.54% | -9.11% | ||
 AMRN | 301.6M | 14.50 | -8.06 | -6.55% | -15.64% | -7.34% | 2.24% | 0.03 |
 CLDX | 2.25B | 33.86 | -8.68 | -78.63% | -172.53% | -49.09% | 0.00 |
Compare ASND vs Peers
Ascendis Pharma A/S (ASND) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ASND Income Statement
Ascendis Pharma A/S (ASND) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.53M | 10.58M | 13.38M | 6.95M | 7.78M | 51.17M | 266.72M | 363.64M | 691.71M |
| Revenue Growth % | -66.78% | 591.57% | 26.41% | -48.02% | 11.87% | 557.93% | 421.2% | 36.34% | 90.22% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 3.52M | 12.14M | 44.4M | 44.26M | 103.18M |
| COGS % of Revenue | - | - | - | - | 45.29% | 23.72% | 16.64% | 12.17% | 14.92% |
| Gross Profit | 1.53M▲ 0% | 10.58M▲ 591.6% | 13.38M▲ 26.4% | 6.95M▼ 48.0% | 4.25M▼ 38.8% | 39.04M▲ 817.4% | 222.32M▲ 469.5% | 319.38M▲ 43.7% | 588.53M▲ 84.3% |
| Gross Margin % | 100% | 100% | 100% | 100% | 54.71% | 76.28% | 83.36% | 87.83% | 85.08% |
| Gross Profit Growth % | -66.78% | 591.57% | 26.41% | -48.02% | -38.8% | 817.44% | 469.52% | 43.66% | 84.27% |
| Operating Expenses | 113.07M | 165.34M | 240.09M | 337.57M | 456.05M | 600.85M | 677.86M | 598.15M | 719.42M |
| OpEx % of Revenue | 7390.26% | 1562.59% | 1795.1% | 4855.07% | 5863.29% | 1174.13% | 254.15% | 164.49% | 104.01% |
| Selling, General & Admin | 13.48M | 25.06M | 48.47M | 76.67M | 160.18M | 215.85M | 258.79M | 284.55M | 435.92M |
| SG&A % of Revenue | 881.18% | 236.81% | 362.42% | 1102.68% | 2059.4% | 421.8% | 97.03% | 78.25% | 63.02% |
| Research & Development | 99.59M | 140.28M | 191.62M | 260.9M | 295.87M | 379.62M | 413.45M | 307M | 283.5M |
| R&D % of Revenue | 6509.09% | 1325.78% | 1432.68% | 3752.39% | 3803.9% | 741.83% | 155.02% | 84.42% | 40.99% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 5.38M | 5.62M | 6.6M | 0 |
| Operating Income | -111.54M▲ 0% | -154.76M▼ 38.7% | -226.72M▼ 46.5% | -330.62M▼ 45.8% | -451.79M▼ 36.6% | -561.81M▼ 24.4% | -455.54M▲ 18.9% | -278.76M▲ 38.8% | -130.89M▲ 53.0% |
| Operating Margin % | -7290.26% | -1462.59% | -1695.1% | -4755.07% | -5808.59% | -1097.85% | -170.8% | -76.66% | -18.92% |
| Operating Income Growth % | -52.96% | -38.74% | -46.5% | -45.83% | -36.65% | -24.35% | 18.92% | 38.81% | 53.05% |
| EBITDA | -110.85M | -153.85M | -220.05M | -321.17M | -436.4M | -544.3M | -436.63M | -261.05M | -113.9M |
| EBITDA Margin % | -7245.2% | -1454.01% | -1645.24% | -4619.19% | -5610.71% | -1063.63% | -163.7% | -71.79% | -16.47% |
| EBITDA Growth % | -53.51% | -38.79% | -43.03% | -45.95% | -35.88% | -24.72% | 19.78% | 40.21% | 56.37% |
| D&A (Non-Cash Add-back) | 689.46K | 908.17K | 6.67M | 9.45M | 15.39M | 17.51M | 18.91M | 17.71M | 17M |
| EBIT | -124.28M | -130.36M | -217.03M | -417.26M | -380.03M | -547.13M | -430.08M | -307.74M | -130.89M |
| Net Interest Income | 826K | 3.89M | 8.84M | -106K | -3.22M | -23.26M | -27.21M | -51.14M | -62.77M |
| Interest Income | 923K | 4.02M | 10.06M | 1.81M | 692K | 7.43M | 16.86M | 14.36M | 14.7M |
| Interest Expense | 97K | 127K | 1.22M | 1.92M | 3.91M | 30.68M | 44.06M | 65.5M | 77.46M |
| Other Income/Expense | -12.83M | 24.27M | 8.47M | -88.55M | 67.85M | -16M | -18.6M | -94.48M | -73.37M |
| Pretax Income | -124.37M▲ 0% | -130.49M▼ 4.9% | -218.25M▼ 67.3% | -419.17M▼ 92.1% | -383.94M▲ 8.4% | -577.82M▼ 50.5% | -474.14M▲ 17.9% | -373.24M▲ 21.3% | -204.26M▲ 45.3% |
| Pretax Margin % | -8129.02% | -1233.26% | -1631.78% | -6028.68% | -4936.28% | -1129.12% | -177.77% | -102.64% | -29.53% |
| Income Tax | -477K | -394K | -234K | -219K | -367K | 5.38M | 7.3M | 4.84M | 14.78M |
| Effective Tax Rate % | 0.38% | 0.3% | 0.11% | 0.05% | 0.1% | -0.93% | -1.54% | -1.3% | -7.23% |
| Net Income | -123.9M▲ 0% | -130.1M▼ 5.0% | -218.02M▼ 67.6% | -418.95M▼ 92.2% | -383.58M▲ 8.4% | -583.19M▼ 52.0% | -481.45M▲ 17.4% | -378.08M▲ 21.5% | -219.03M▲ 42.1% |
| Net Margin % | -8097.84% | -1229.53% | -1630.03% | -6025.53% | -4931.56% | -1139.63% | -180.51% | -103.97% | -31.67% |
| Net Income Growth % | -80.86% | -5% | -67.58% | -92.17% | 8.44% | -52.04% | 17.45% | 21.47% | 42.07% |
| Net Income (Continuing) | -123.9M | -130.1M | -218.02M | -418.95M | -383.58M | -583.19M | -481.45M | -378.08M | -219.03M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.68▲ 0% | -3.17▲ 13.9% | -4.69▼ 47.9% | -8.28▼ 76.5% | -7.00▲ 15.5% | -10.40▼ 48.6% | -8.55▲ 17.8% | -6.53▲ 23.6% | -3.62▲ 44.6% |
| EPS Growth % | -42.64% | 13.86% | -47.95% | -76.55% | 15.46% | -48.57% | 17.79% | 23.63% | 44.56% |
| EPS (Basic) | -3.68 | -3.17 | -4.69 | -8.28 | -7.00 | -10.40 | -8.55 | -6.53 | -3.62 |
| Diluted Shares Outstanding | 33.63M | 41.09M | 46.51M | 50.62M | 54.77M | 56.07M | 56.29M | 57.89M | 60.61M |
| Basic Shares Outstanding | 33.63M | 41.09M | 46.51M | 50.62M | 54.77M | 56.07M | 56.29M | 57.89M | 60.61M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ASND Balance Sheet
Ascendis Pharma A/S (ASND) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 204.63M | 292.91M | 611.17M | 740.13M | 805.89M | 923.47M | 702.72M | 1.06B | 1.11B |
| Cash & Short-Term Investments | 195.35M | 277.86M | 598.11M | 718.79M | 682.06M | 735.46M | 399.44M | 559.54M | 615.78M |
| Cash Only | 195.35M | 277.86M | 598.11M | 584.52M | 446.27M | 444.77M | 392.16M | 559.54M | 615.78M |
| Short-Term Investments | 0 | 0 | 0 | 134.28M | 235.8M | 290.69M | 7.28M | 0 | 0 |
| Accounts Receivable | 188K | 6K | 804K | 387K | 2.2M | 11.91M | 35.87M | 166.28M | 157.63M |
| Days Sales Outstanding | 44.85 | 0.21 | 21.94 | 20.32 | 103.24 | 84.95 | 49.09 | 166.9 | 83.18 |
| Inventory | 0 | 0 | 0 | 0 | 75.41M | 130.67M | 208.93M | 295.61M | 301.4M |
| Days Inventory Outstanding | - | - | - | - | 7.81K | 3.93K | 1.72K | 2.44K | 1.07K |
| Other Current Assets | 2.19M | 2.62M | 4.61M | 6.96M | 20.99M | 13.72M | 19.9M | 11.16M | 0 |
| Total Non-Current Assets | 6.34M | 26.06M | 65.56M | 239.66M | 279.04M | 166.27M | 122.87M | 118.63M | 193.5M |
| Property, Plant & Equipment | 2.56M | 4.33M | 45.07M | 108.11M | 126.05M | 129.09M | 110.63M | 98.71M | 146.42M |
| Fixed Asset Turnover | 0.60x | 2.45x | 0.30x | 0.06x | 0.06x | 0.40x | 2.41x | 3.68x | 4.72x |
| Goodwill | 3.5M | 3.5M | 3.5M | 3.5M | 3.5M | 3.5M | 3.5M | 3.5M | 3.49M |
| Intangible Assets | 0 | 0 | 0 | 2.22M | 1.78M | 1.33M | 924K | 533K | 214.91K |
| Long-Term Investments | 0 | 17.08M | 15.54M | 124.46M | 145.91M | 30.42M | 5.69M | 13.57M | 43.38M |
| Other Non-Current Assets | 293K | 1.16M | 1.46M | 1.38M | 1.81M | 1.92M | 2.13M | 2.32M | 0 |
| Total Assets | 210.98M▲ 0% | 318.97M▲ 51.2% | 676.73M▲ 112.2% | 979.79M▲ 44.8% | 1.08B▲ 10.7% | 1.09B▲ 0.4% | 825.59M▼ 24.2% | 1.18B▲ 42.9% | 1.3B▲ 10.4% |
| Asset Turnover | 0.01x | 0.03x | 0.02x | 0.01x | 0.01x | 0.05x | 0.32x | 0.31x | 0.53x |
| Asset Growth % | 11% | 51.18% | 112.16% | 44.78% | 10.73% | 0.44% | -24.24% | 42.87% | 10.39% |
| Total Current Liabilities | 23.77M | 38.92M | 47.99M | 52.8M | 100.36M | 716.78M | 736.51M | 907.86M | 1.07B |
| Accounts Payable | 17.43M | 19.74M | 27.77M | 21.9M | 59.42M | 101.03M | 94.57M | 96.39M | 90.62M |
| Days Payables Outstanding | - | - | - | - | 6.16K | 3.04K | 777.49 | 794.97 | 320.56 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 7M | 412.98M | 421.27M | 491.54M | 486.32M |
| Deferred Revenue (Current) | 0 | 6.9M | 858K | 363K | 2.6M | 0 | 1.18M | 936K | 4.94M |
| Other Current Liabilities | 0 | 0 | 13.35M | 23.38M | 24.15M | 183.49M | 203.02M | 317.77M | 480.63M |
| Current Ratio | 8.61x | 7.53x | 12.74x | 14.02x | 8.03x | 1.29x | 0.95x | 1.17x | 1.04x |
| Quick Ratio | 8.61x | 7.53x | 12.74x | 14.02x | 7.28x | 1.11x | 0.67x | 0.84x | 0.76x |
| Cash Conversion Cycle | - | - | - | - | 1.76K | 976.35 | 989.36 | 1.81K | 828.84 |
| Total Non-Current Liabilities | 0 | 0 | 31.63M | 88.28M | 100.93M | 109.61M | 234.78M | 377.34M | 395.83M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 97.97M | 95.4M | 223M | 365.08M | 385.09M |
| Capital Lease Obligations | 0 | 0 | 30.72M | 85.12M | 97.97M | 95.4M | 84.62M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 5.83M | 7.26M | 9.62M |
| Other Non-Current Liabilities | 0 | 0 | 908K | 3.16M | -97.97M | -95.4M | -84.62M | 0 | 0 |
| Total Liabilities | 23.77M | 38.92M | 79.62M | 141.08M | 201.29M | 826.39M | 971.28M | 1.29B | 1.46B |
| Total Debt | 0 | 0 | 36.62M | 91.97M | 209.92M | 617.57M | 743.06M | 856.62M | 871.41M |
| Net Debt | -195.35M | -277.86M | -561.49M | -492.54M | -236.34M | 172.8M | 350.89M | 297.07M | 255.64M |
| Debt / Equity | - | - | 0.06x | 0.11x | 0.24x | 2.35x | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -1281.21x | -1026.49x | -177.75x | -217.55x | -97.17x | -17.83x | -9.76x | -4.70x | -1.69x |
| Total Equity | 187.21M▲ 0% | 280.05M▲ 49.6% | 597.11M▲ 113.2% | 838.71M▲ 40.5% | 883.63M▲ 5.4% | 263.35M▼ 70.2% | -145.7M▼ 155.3% | -105.71M▲ 27.4% | -162.75M▼ 54.0% |
| Equity Growth % | 6% | 49.59% | 113.22% | 40.46% | 5.36% | -70.2% | -155.32% | 27.45% | -53.97% |
| Book Value per Share | 5.57 | 6.82 | 12.84 | 16.57 | 16.13 | 4.70 | -2.59 | -1.83 | -2.69 |
| Total Shareholders' Equity | 187.21M | 280.05M | 597.11M | 838.71M | 883.63M | 263.35M | -145.7M | -105.71M | -162.75M |
| Common Stock | 4.97M | 5.66M | 6.44M | 7.22M | 7.65M | 7.67M | 7.75M | 8.15M | 8.32M |
| Retained Earnings | -263.21M | -393.31M | -611.32M | -1.03B | -1.24B | -1.86B | -2.28B | -2.56B | -2.7B |
| Treasury Stock | 0 | 0 | 0 | 0 | -21K | -149K | -146K | -113K | -79.97K |
| Accumulated OCI | 22.78M | 42.45M | 79.9M | 133.02M | 3.78M | 3.45M | 721K | 1.78M | -1.75M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ASND Cash Flow Statement
Ascendis Pharma A/S (ASND) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -95.1M | -138.8M | -175.94M | -271.55M | -417.65M | -495.7M | -467.36M | -306.2M | 51.77M |
| Operating CF Margin % | -6215.62% | -1311.8% | -1315.41% | -3905.48% | -5369.62% | -968.65% | -175.23% | -84.2% | 7.48% |
| Operating CF Growth % | -58.03% | -45.96% | -26.75% | -54.34% | -53.8% | -18.69% | 5.72% | 34.48% | 116.91% |
| Net Income | -123.9M | -130.1M | -218.02M | -418.95M | -383.58M | -583.19M | -481.45M | -378.08M | -219.03M |
| Depreciation & Amortization | 734K | 880K | 6.69M | 9.45M | 15.39M | 17.96M | 18.91M | 17.71M | 17M |
| Stock-Based Compensation | 9.71M | 19.65M | 37.49M | 53.17M | 66.83M | 64.18M | 66.66M | 95.51M | 0 |
| Deferred Taxes | -477K | -394K | -234K | -219K | -367K | 5.38M | 0 | 4.84M | 3.21M |
| Other Non-Cash Items | 13.81M | -30.55M | -5.93M | 85.97M | -68.2M | 12.45M | 24.77M | 60.98M | 182.44M |
| Working Capital Changes | 5.02M | 1.71M | 4.07M | -964K | -47.72M | -12.47M | -96.26M | -107.16M | 68.16M |
| Change in Receivables | 99K | 182K | -1.87M | -2M | -6.66M | -11.53M | -32.77M | -118.61M | 14.97M |
| Change in Inventory | -5.71M | 0 | -5.64M | 0 | -75.41M | -55.27M | -78.26M | -86.68M | -5.69M |
| Change in Payables | 10.76M | 8.26M | 7.51M | 0 | 0 | 0 | 0 | 0 | -9.96M |
| Cash from Investing | -941K | -2.65M | -5.16M | -291.2M | -110.58M | 61.73M | 286.47M | 6.88M | -8.15M |
| Capital Expenditures | -941K | -2.65M | -5.16M | -19.86M | -23.7M | -14.49M | -2.44M | -1.43M | -8.15M |
| CapEx % of Revenue | 61.5% | 25.03% | 38.57% | 285.63% | 304.76% | 28.31% | 0.92% | 0.39% | 1.18% |
| Acquisitions | 0 | 0 | 0 | 0 | -10.19M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 3.36M | -530K | 9.54M | 288.92M | 950K | 0 |
| Cash from Financing | 124.72M | 203.27M | 493.59M | 602.65M | 351.39M | 396.77M | 134.29M | 443.93M | 34.89M |
| Debt Issued (Net) | 0 | 0 | -4.04M | -4.77M | -6.43M | 496.93M | 125.82M | 122.79M | -21.09M |
| Equity Issued (Net) | 133.11M | 216.38M | 480.25M | 580.54M | 346.28M | -105.31M | -1.81M | 309.91M | 66.93M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -21.61M | -105.31M | -1.81M | 0 | -16.71M |
| Other Financing | -8.39M | -13.12M | 17.38M | 26.88M | 11.54M | 5.15M | 10.29M | 11.22M | -10.95M |
| Net Change in Cash | 15.02M▲ 0% | 82.51M▲ 449.3% | 320.24M▲ 288.1% | -13.59M▼ 104.2% | -138.25M▼ 917.4% | -1.5M▲ 98.9% | -52.6M▼ 3406.9% | 167.38M▲ 418.2% | 122.65M▼ 26.7% |
| Free Cash Flow | -96.04M▲ 0% | -141.45M▼ 47.3% | -181.09M▼ 28.0% | -293.1M▼ 61.8% | -441.88M▼ 50.8% | -510.19M▼ 15.5% | -469.8M▲ 7.9% | -307.62M▲ 34.5% | 43.62M▲ 114.2% |
| FCF Margin % | -6277.12% | -1336.83% | -1353.98% | -4215.45% | -5681.19% | -996.97% | -176.14% | -84.6% | 6.31% |
| FCF Growth % | -57.83% | -47.28% | -28.03% | -61.85% | -50.76% | -15.46% | 7.92% | 34.52% | 114.18% |
| FCF per Share | -2.86 | -3.44 | -3.89 | -5.79 | -8.07 | -9.10 | -8.35 | -5.31 | 0.72 |
| FCF Conversion (FCF/Net Income) | 0.77x | 1.07x | 0.81x | 0.65x | 1.09x | 0.85x | 0.97x | 0.81x | -0.24x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 15.67M | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ASND Key Ratios
Ascendis Pharma A/S (ASND) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -46.14% | -68.11% | -55.68% | -49.71% | -58.36% | -44.54% | -101.69% | -818.43% | - | - |
| Return on Invested Capital (ROIC) | - | - | -5304.74% | -899.32% | -129.89% | -68.22% | -77.78% | -106.54% | -105.44% | -69.07% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 54.71% | 76.28% | 83.36% | 87.83% | 85.08% |
| Net Margin | -1487.3% | -8097.84% | -1229.53% | -1630.03% | -6025.53% | -4931.56% | -1139.63% | -180.51% | -103.97% | -31.67% |
| Debt / Equity | - | - | - | 0.06x | 0.11x | 0.24x | 2.35x | - | - | - |
| Interest Coverage | -13745.40x | -1281.21x | -1026.49x | -177.75x | -217.55x | -97.17x | -17.83x | -9.76x | -4.70x | -1.69x |
| FCF Conversion | 0.88x | 0.77x | 1.07x | 0.81x | 0.65x | 1.09x | 0.85x | 0.97x | 0.81x | -0.24x |
| Revenue Growth | -43.26% | -66.78% | 591.57% | 26.41% | -48.02% | 11.87% | 557.93% | 421.2% | 36.34% | 90.22% |
ASND Frequently Asked Questions
Ascendis Pharma A/S (ASND) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ascendis Pharma A/S (ASND) reported $717.8M in revenue for fiscal year 2025. This represents a 4506% increase from $15.6M in 2012.
Ascendis Pharma A/S (ASND) grew revenue by 90.2% over the past year. This is strong growth.
Ascendis Pharma A/S (ASND) reported a net loss of $227.7M for fiscal year 2025.
Dividend & Returns
Ascendis Pharma A/S (ASND) generated $42.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More ASND
Ascendis Pharma A/S (ASND) financial analysis — history, returns, DCA and operating performance tools
Full ASND Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates